Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

human umbilical vein endothelial cells (HUVECs)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	VEGFR (9) Akt (3) Antibiotic (1) Apoptosis (2) Bacterial (2) Bcl-2 Family (1) c-Kit (1) Calcium Channel (3) Caspase (1) Endogenous Metabolite (3) ERK (2) FAK (1) Ferroptosis (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Demethylase (1) HSP (1) HSV (1) Insulin Receptor (1) Integrin (5) mAChR (1) mTOR (1) NF-κB (3) NOD-like Receptor (NLR) (1) p38 MAPK (2) Parasite (1) PDGFR (1) PKC (2) PPAR (2) Raf (2) Reactive Oxygen Species (2) SF3B1 (1) Sodium Channel (1) Src (2) STAT (1)
By Research Areas:	Cancer (15) Cardiovascular Disease (6) Infection (4) Inflammation/Immunology (9) Metabolic Disease (1) Neurological Disease (1)

By Targets:

VEGFR (9)

Akt (3)

Antibiotic (1)

Apoptosis (2)

Bacterial (2)

Bcl-2 Family (1)

c-Kit (1)

Calcium Channel (3)

Caspase (1)

Endogenous Metabolite (3)

ERK (2)

FAK (1)

Ferroptosis (1)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Demethylase (1)

HSP (1)

HSV (1)

Insulin Receptor (1)

Integrin (5)

mAChR (1)

mTOR (1)

NF-κB (3)

NOD-like Receptor (NLR) (1)

p38 MAPK (2)

Parasite (1)

PDGFR (1)

PKC (2)

PPAR (2)

Raf (2)

Reactive Oxygen Species (2)

SF3B1 (1)

Sodium Channel (1)

Src (2)

STAT (1)

By Research Areas:

Cancer (15)

Cardiovascular Disease (6)

Infection (4)

Inflammation/Immunology (9)

Metabolic Disease (1)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: VEGFR Nuclear Factor of activated T Cells (NFAT) TREM receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-137388A

p-F-HHSiD hydrochloride p-Fluorohexahydrosiladifenidol hydrochloride	mAChR	Neurological Disease
p-F-HHSiD (p-Fluorohexahydrosiladifenidol) hydrochloride is a selective M3 mAChR antagonist. p-F-HHSiD hydrochloride blocks Acetylcholine-mediated vasodilatation in human umbilical vein endothelial cells (HUVECs) .

HY-N6737

Aureothricin	Bacterial Antibiotic	Infection
Aureothricin is a dithiolopyrrolone (DTP) antibiotic first isolated from Streptomyces and exhibits relatively broad-spectrum antibiotic activity. Aureothricin can inhibit adhesion of human umbilical vein endothelial cells (HUVECs) to vitronectin .

HY-W588250

Surfactin C1	Integrin	Inflammation/Immunology
Surfactin C1 is an amphiphilic biosurfactants. Surfactin C1 inhibits leukemic cell (HL-60) adhesion to human umbilical vein endothelial cells (HUVEC). Surfactin C1 inhibits adhesion melecules expression, such as ICAM-1 and VCAM-1 .

HY-W800162

VEGFR-2-IN-37	VEGFR	Cancer
VEGFR-2-IN-37 (compound 12) is an inhibitor of VEGFR-2. The inhibition rate at 200 μM was approximately 56.9 μM. VEGFR-2-IN-37 is a potential inhibitor of human umbilical vein endothelial cell (HUVEC) proliferation .

HY-125919

Vulpinic acid	Reactive Oxygen Species Bacterial Endogenous Metabolite	Infection Inflammation/Immunology
Vulpinic acid, a lichen metabolite, decreases H₂O₂-induced ROS production, oxidative stress and oxidative stress-related damages in human umbilical vein endothelial cells (HUVEC). Vulpinic acid is active against staphylococci, enterococci, and anaerobic bacteria.Vulpinic acid has the potential for atherosclerosis research .

HY-P5877

ɛPKC(85–92),Myristoylated	PKC	Inflammation/Immunology
PKC(85–92),Myristoylated is a cell permeable myristic acid conjugated PKC peptide activator that enhances NO release in cultured human umbilical vein endothelial cells (HUVECs) .

HY-P5888

PKCε inhibitor peptide,myristoylated Myr‐PKCɛ-	PKC	Inflammation/Immunology
PKCε inhibitor peptide,myristoylated (Myr‐PKC -) is a cell permeable myristic acid conjugated PKC peptide inhibitor that attenuates NO release in cultured human umbilical vein endothelial cells (HUVECs) .

HY-118622

Isogentisin	Others	Others
Isogentisin is a cell protector. Isogentisin can shield human umbilical vein endothelial cells (HUVEC) from cell death caused by H₂0₂ and UV exposure. Isogentisin can also prevent endothelial damage triggered by smoking by activating cell repair functions to promote cell survival .

HY-163881

VEGFR-IN-5	VEGFR	Cancer
VEGFR-IN-5 (compound 9k) is a potent inhibitor of VEGFR2, with the IC₅₀ of 8.4 nM and an acceptable oral bioavailability. VEGFR-IN-5 inhibits migration and invasion of human umbilical vein endothelial cells (HUVEC) cells and induces apoptosis .

HY-149921

Antiangiogenic agent 3	Src p38 MAPK	Cancer
Antiangiogenic agent 3 (compound 3) is a potent antiangiogenic agent. Antiangiogenic agent 3 is an inhibitor of human umbilical vein endothelial cells (HUVEC). Antiangiogenic agent 3 inhibits HUVEC migration and chemotactic motilities. Antiangiogenic agent 3 also decreases the gene expression of Src, cdc42, and MAPK .

HY-N2927

Costic acid β-Costic acid	Parasite	Infection
Costic acid (β-Costic acid) is a natural product, that can be isolated from Dittrichia viscosa. Costic acid exhibits potent in vivo acaricidal activity against the parasite. Costic acid is not toxic for human umbilical vein endothelial cells (HUVEC) at concentrations of up to 230 μM. Costic acid can be used for the research of varroosis in honey bee colonies .

HY-W013557

3-Hydroxyxanthone 3-Hydroxy-xanthen-9-one	Integrin	Inflammation/Immunology
3-Hydroxyxanthone (3-Hydroxy-xanthen-9-one) is a xanthone compound, with . 3-Hydroxyxanthone inhibits NADPH-catalysed lipid peroxidation in human umbilical vein endothelial cells (HUVECs). 3-Hydroxyxanthone also inhibits TNF-alpha induced ICAM-1 expression .

HY-N15264

Azaspirene (-)-Azaspirene	VEGFR Raf	Cancer
Azaspirene ((-)-Azaspirene) is an angiogenesis and Raf-1 activation inhibitor isolated from the fungus Neosartorya sp. Azaspirene inhibits vascular endothelial growth factor (VEGF)-induced human umbilical vein endothelial cell (HUVEC) migration and Raf-1 activation, but has no effect on the activation of kinase insert domain-containing receptor/fetal liver kinase 1 (VEGF receptor 2) .

HY-164551

YLL545	VEGFR STAT ERK Apoptosis	Cancer
YLL545 is a type of vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor. YLL545 can inhibit VEGF-induced phosphorylation of VEGFR2 and the activation of downstream signaling factors (like phosphorylated STAT3 and phosphorylated ERK1/2) in human umbilical vein endothelial cells (HUVEC). YLL545 can suppress the proliferation, migration, invasion, and angiogenesis of HUVEC. YLL545 can induce apoptosis in breast cancer mice and inhibit tumor growth .

HY-P99333

Volociximab 1 Publications Verification M200; Eos 200-4	Integrin	Cardiovascular Disease Cancer
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC₅₀=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .

HY-13645

Henatinib	VEGFR c-Kit PDGFR	Cancer
Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities. Henatinib inhibits the activity of VEGFR-2, c-kit, PDGFR with IC₅₀ values of 0.6 nM, 3.3 nM and 41.5 nM, respectively. Henatinib significantly inhibits VEGFR-2 phosphorylation and its downstream signal pathway in human umbilical vein endothelial cells (HUVECs) .

HY-133924

18-Deoxyherboxidiene RQN-18690A	SF3B1	Cardiovascular Disease Cancer
18-Deoxyherboxidiene (RQN-18690A) is a potent angiogenesis inhibitor. 18-Deoxyherboxidiene targets SF3b, a spliceosome component that is a subcomplex of the U2 small nuclear ribonucleoprotein (snRNP) in the spliceosome. 18-Deoxyherboxidiene inhibits the migration and tube formation of human umbilical vein endothelial cells (HUVECs) without significant cell toxicity. 18-Deoxyherboxidiene has the potential for cancer research .

HY-120200

YF-452	VEGFR	Cardiovascular Disease Cancer
YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic agent candidate for cancer research .

HY-B0987

Ascorbyl palmitate 3 Publications Verification L-Ascorbic acid 6-hexadecanoate; 6-O-Palmitoyl-L-ascorbic acid	Reactive Oxygen Species Endogenous Metabolite Calcium Channel Sodium Channel Apoptosis NOD-like Receptor (NLR) Bcl-2 Family Caspase	Inflammation/Immunology
Ascorbyl palmitate is an orally active ester formed from ascorbic acid and palmitic acid, used as an antioxidant and food additive. Ascorbyl palmitate in preventing fat and oil oxidation is more efficient than Butylated hydroxyanisole (HY-B1066) and Butylated hydroxytoluene (HY-Y0172). Ascorbyl palmitate mitigates inhibition of collagen synthesis by select calcium and sodium channel blockers. Ascorbyl palmitate induces Apoptosis in human umbilical vein endothelial cells (HUVECs). Ascorbyl palmitate ameliorates inflammatory diseases by inhibition of NLRP3 inflammasome .

HY-148877

AT-533	HSP HSV HIF/HIF Prolyl-Hydroxylase VEGFR NF-κB ERK Akt FAK	Infection Inflammation/Immunology Cancer
AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including Akt/mTOR/p70S6K, Erk1/2 and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs) .

HY-N0515

Ophiopogonin D	PPAR NF-κB Calcium Channel	Cardiovascular Disease Inflammation/Immunology
Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C₂₉ steroidal glycoside . Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca ²⁺ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D has been used to treat inflammatory and cardiovascular diseases for thousands of years .

HY-155721

22-(4′-py)-JA 22-(4′-Pyridinecarbonyl) jorunnamycin A	Akt mTOR	Cancer
22-(4′-py)-JA is a semisynthetic derivative of junamycin A (JA) that can be isolated from the Thai blue sponge (Xestospongia sp.). 22-(4′-py)-JA has antimetastatic activity and can inhibit AKT/mTOR/p70S6K signaling. 22-(4′-py)-JA inhibits tumor cell invasion and tube formation in human umbilical vein endothelial cells (HUVEC), downregulates metalloproteinases (MMP-2 and MMP-9), hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF). 22-(4′-py)-JA has potent anticancer activity against non-small cell lung cancer (NSCLC) .

HY-W342441

Monosialoganglioside GM3 (bovine)	VEGFR Akt Ferroptosis Insulin Receptor	Metabolic Disease Cancer
Monosialoganglioside GM3 (bovine) is a monosialoganglioside and an inhibitor of VEGFR2 and Akt. At a concentration of 20 μM, Monosialoganglioside GM3 inhibits angiogenesis and reduces the proliferation and migration of human umbilical vein endothelial cells (HUVECs) by inhibiting VEGFR2 and Akt phosphorylation. Ganglioside GM3 also inhibits ferroptosis, providing protective effects during the formation of abdominal aortic aneurysms. Additionally, Monosialoganglioside GM3 (bovine) acts as an inhibitor of insulin signaling, inducing the dissociation of the insulin receptor (IR)-Caveolin-1 complex from lipid microdomains and causing insulin resistance in adipocytes. Monosialoganglioside GM3 (bovine) can be used in cancer and metabolic disease research .

HY-N0515R

Ophiopogonin D (Standard)	PPAR NF-κB Calcium Channel	Cardiovascular Disease Inflammation/Immunology
Ophiopogonin D (Standard) is the analytical standard of Ophiopogonin D. This product is intended for research and analytical applications. Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C29 steroidal glycoside . Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca2+ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D has been used to treat inflammatory and cardiovascular diseases for thousands of years .

HY-113038AR

α-Hydroxyglutaric acid (disodium) (Standard)	Histone Demethylase Endogenous Metabolite	Cancer
Ophiopogonin D (Standard) is the analytical standard of Ophiopogonin D. This product is intended for research and analytical applications. Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C29 steroidal glycoside . Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca2+ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D has been used to treat inflammatory and cardiovascular diseases for thousands of years .

HY-164530

SKLB646	Src VEGFR Raf p38 MAPK	Cancer
SKLB646 is an orally active multi-target kinase inhibitor. SKLB646 shows significant inhibitory effects on SRC and VEGFR2 with IC₅₀ values ??of 0.002 μmol/L and 0.012 μmol/L, respectively. SKLB646 also shows significant inhibitory effects on B-Raf and C-Raf with IC₅₀ values ??of 0.022 μmol/L and 0.019 μmol/L, respectively. SKLB646 inhibits the activation of the SRC signaling pathway and blocks the MAPK signaling pathway by inhibiting Raf kinase. In addition, SKLB646 can inhibit the proliferation, migration and invasion of human umbilical vein endothelial cells (HUVEC) to inhibit tumor-induced angiopoietic formation. SKLB646 shows significant anti-proliferative and anti-survival activities against triple-negative breast cancer (TNBC) cell lines .

HY-P3522

REDV	Integrin	Cardiovascular Disease
REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion. REDV is used to study the effects of gene vectors containing REDV on cells .

HY-P3522A

REDV TFA	Integrin	Cancer
REDV TFA is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV TFA can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV TFA can be used for the research of cell adhesion .

Cat. No.	Product Name	Target	Research Area